In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of cases of pancreatic cancer, and prognosis for PDAC remains poor despite treatment advances. One reason is that PDAC downregulates ...

Increase seen across age groups, while incidence of colorectal adenocarcinoma increased most in those aged 15 to 34 years.

Rates of pancreatic adenocarcinoma increased significantly among younger individuals than older ones. Colorectal adenocarcinoma diagnoses also have increased among patients aged 15 to 34 years.

From 2000 to 2021, the incidence of pancreatic adenocarcinoma rose among all age groups in the United States, with the highest increase in those aged 15-34 years. During the same period ...

Between 2000 and 2021, there was an increased incidence of pancreatic adenocarcinoma and a decrease in the incidence of colorectal cancer seen across age groups. HealthDay News — From 2000 to ...

Between 2000 and 2021, the incidence of pancreatic adenocarcinoma increased across all age groups, with the highest annual percentage change (APC) of 4.35% in individuals aged 15–34 years.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic ...

Colorectal adenocarcinoma incidence is decreasing overall but increasing among individuals aged 15 to 34 years, with an APC of 1.75. Pancreatic adenocarcinoma incidence is rising across all age ...

Zenocutuzumab is the first FDA-approved treatment for NRG1-positive NSCLC and pancreatic adenocarcinoma. The eNRGy study demonstrated a 33% overall response rate in NSCLC and 40% in pancreatic ...

Bizengri received FDA approval for NSCLC and pancreatic adenocarcinoma with NRG1 gene fusion after prior therapy failure. The eNRGy study showed a 33% ORR in NSCLC and 40% in pancreatic adenocarcinoma ...